What were the key takeaways from Alphatec Holdings's earnings call?

Did Alphatec Holdings beat or miss consensus estimates last quarter?

What does Alphatec Holdings do and what are its main business segments?

What is the market's earnings forecast for Alphatec Holdings next quarter?

What guidance did Alphatec Holdings's management provide for the next earnings period?

What is Alphatec Holdings's gross profit margin?

What is the revenue and EPS growth rate for Alphatec Holdings year over year?

What is Alphatec Holdings's latest dividend and current dividend yield?

- **Revenue Growth Acceleration**: 25% YoY to $764 million, driven by 21% surgical and 14% EOS revenue growth.
- **Profitability Expansion**: 12% EBITDA margin in 2025, guided to 15% in 2026 with $134 million EBITDA.
- **Cash Flow Turnaround**: 2025 marks first year of positive free cash flow ($3 million), with $20 million+ expected in 2026.
- **Strategic Product Momentum**: Valence navigation platform and EOS Insight imaging system driving deformity surgery adoption.
- **2026 Outlook**: 17% revenue growth to $890 million, 71% gross margin target, and $20 million+ free cash flow.

**【CEO Summary Section】**
- Q4 2025 revenue: $213 million (20% YoY growth), with 21% surgical revenue growth and 14% EOS revenue growth.
- Full-year 2025 revenue: $764 million (25% YoY growth), including $93 million adjusted EBITDA (12% of revenue) and $3 million free cash flow.
- Strategic focus on lateral and deformity spine surgery, with new products like Valence navigation platform and EOS Insight imaging system.
- 2026 outlook: $890 million revenue, $134 million adjusted EBITDA (15% margin), and $20 million free cash flow.

**【CFO Financial Commentary】**
- Q4 2025 financials: 70.5% non-GAAP gross margin, $33 million adjusted EBITDA (35% drop-through), and $8 million free cash flow.
- Full-year 2025 metrics: 70.2% gross margin, 59% SG&A as a % of sales, and 12% EBITDA margin.
- 2026 guidance: 17% revenue growth, 71% gross margin target, and 400+ basis points operating margin expansion.
- Cash position: $161 million at quarter-end, with $221 million total liquidity.

**【Q&A Key Highlights】**
- **Revenue Seasonality**: 2026 expected to follow 2025 pattern (22% Q1, 25% Q2/Q3, 28% Q4), with higher EBITDA drop-through in Q1.
- **Sales Talent Attraction**: ATEC is the 'preferred destination' for top sales talent due to procedural ecosystem differentiation and growth opportunities.
- **Valence Launch**: Controlled release in 2026, targeting Stealth replacement cycle and robotic-assisted surgery adoption.
- **Bone Graft Partnership**: Exclusive deal with Adaptive Biotechnologies for advanced BNP, projected to be market-leading in 2028+.


Alphatec Holdings, Inc.(ATEC)-20260225-2025 Q4 Earnings call transcript

- **Revenue Growth Accelerates**: Q3 2025 revenue up 30% YoY to $197 million, with surgical revenue at $177 million (+31% YoY).
- **Profitability Expansion**: Adjusted EBITDA margin expanded 840 basis points YoY to 13%, with free cash flow turning positive for the first time.
- **Strategic Catalysts**: EOS integration, Valence system launch, and AI-driven alignment tools position for 2026 growth.
- **Surgeon Adoption Surge**: 26% net new surgeon users Q3, with 30% same-store sales growth in established markets.
- **2027 Targets On Track**: Projected $1 billion revenue and $65 million free cash flow by 2027, with 2026 free cash flow guidance of $20 million.
- **Deformity Market Expansion**: EOS biplanar imaging and AI tools driving early-stage deformity market penetration.


**【CEO Summary Section】**
- Highlighted 30% year-over-year revenue growth to $197 million, driven by surgical and EOS revenue streams.
- Emphasized durable growth through proceduralization in lateral, cervical, and deformity markets.
- Highlighted EOS integration, Valence system launch, and AI-driven alignment tools as key future catalysts.
- Noted 26% net new surgeon user growth and 30% same-store sales growth in established territories.
- Highlighted free cash flow of $5 million and trailing 12-month EBITDA of $81 million.

**【CFO Financial Commentary】**
- Reported Q3 2025 revenue of $197 million (+30% YoY), with surgical revenue at $177 million (+31% YoY) and EOS revenue at $20 million.
- Gross margin maintained at 70%, with R&D expenses up 27% YoY to $15 million.
- Operating expenses leveraged 980 basis points YoY, driving adjusted EBITDA of $26 million (13% of revenue).
- Raised full-year 2025 revenue guidance to $760 million (+$18 million) and EBITDA guidance to $91 million.
- Projected 2026 free cash flow in the $20 million range, with long-term 2027 targets of $1 billion revenue and $65 million free cash flow.

**【Q&A Key Highlights】**
- **Cash Flow & Growth Balance**: CFO noted 2026 free cash flow guidance of $20 million, with plans to update long-range plan in late 2026. CEO emphasized durable growth through surgeon adoption (30% same-store sales) and infrastructure investments.
- **Competitive Landscape**: CEO highlighted disruption from industry consolidation, with ATEC focused on proceduralization and EOS integration. CFO noted share gains across all competitors.
- **Valence Launch**: CEO described Valence as a democratizing tool for lateral surgery, with Q4 2025 launch and 2026 adoption acceleration. CFO noted cautious rollout to ensure success.
- **International Expansion**: CFO reaffirmed 2027 LRP targets of $30 million international surgical revenue, with EOS driving deformity market penetration.
- **Deformity Market**: CEO highlighted EOS biplanar imaging and AI-driven alignment as early-stage opportunities, with 2026 product pipeline additions.
- **Surgeon Adoption**: CFO noted 26% quarterly net new surgeon users and 840 basis points of EBITDA margin expansion YoY, driven by infrastructure leverage.


Alphatec Holdings, Inc. (ATEC) Q3 2025 Earnings Call Transcript

- **Revenue Growth Leader**: 29% surgical revenue growth vs. 6x market rate, driven by 21% new surgeon adoption.
- **Profitability Breakthrough**: $23M EBITDA (13% margin), 4x YoY improvement, with first quarter of non-GAAP net income.
- **Cash Flow Inflection**: $5M free cash flow, $217M cash on hand, and no debt.
- **Strategic Momentum**: EOS imaging adoption accelerating, Valence robotics launching in 2026, and 20%+ organic growth guided for 2025.

**【CEO Opening Remarks】**
- **Revenue Growth**: Total revenue of $186 million (+27% YoY), with surgical revenue at $168 million (+29% YoY), driven by 21% new surgeon adoption and 6% utilization increase.
- **Profitability**: Adjusted EBITDA of $23 million (13% of revenue), up 4x YoY, with $5 million free cash flow. Trailing 12-month EBITDA is $62 million.
- **Market Position**: Third-largest U.S. spine player, with clinical distinction through EOS imaging, SafeOp neurophysiology, and PTP/lateral surgery techniques.
- **Cash Position**: $217 million in cash, with no debt, supporting long-term growth.

**【CFO Financial Commentary】**
- **Top Line**: Q2 revenue beat by $40 million YoY, driven by 28% procedural volume growth. Same-store sales in U.S. up 29% YoY.
- **Margins**: Non-GAAP gross margin 70%, R&D 8% of sales, SG&A 58% of sales (down 1,100 bps YoY). Operating margin expanded 1,100 bps YoY.
- **Cash Flow**: $5 million free cash flow (vs. $0-$5M guidance), with $16 million operating cash flow. Full-year free cash flow expected positive.
- **Guidance Update**: Full-year revenue raised to $742 million (+20% YoY), EBITDA to $83 million (11% margin).

Alphatec Holdings, Inc. (ATEC) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: 22% YoY to $169 million, driven by 24% surgical growth and 18% surgeon adoption expansion.
- **Profitability**: Adjusted EBITDA of $11 million (6% margin), 900bps margin expansion YoY.
- **Cash Flow**: Q1 cash burn at $15 million, with full-year positive cash flow expected.
- **Strategic Wins**: EOS order book +28% YoY, robotic system Q4 2025 launch, and 23% same-store sales growth.
- **Risks**: Low single-digit million tariff impact on EOS imports in H2 2025.


**【CEO Opening Remarks】**
- Q1 2025 revenue reached $169 million, up 22% YoY, with surgical revenue growing 24% and EOS revenue up 8%.
- Surgical volume increased 17%, driven by 18% growth in surgeon adoption and 6% rise in revenue per procedure.
- Adjusted EBITDA of $11 million (6% margin), second-highest quarterly performance, with cash burn at $15 million, lowest end of guidance range.
- EOS order book grew 28% YoY, signaling strong demand for informatics solutions.

**【CFO Financial Highlights】**
- Non-GAAP gross margin: 70% (down 50bps YoY due to product mix).
- Operating expenses: $124 million (74% of sales), up 8% YoY but 900bps margin expansion.
- Free cash flow: $15 million use, with full-year positive cash flow expected.
- 2025 guidance: Revenue $734 million (20% growth), adjusted EBITDA $78 million (11% margin).

**【Q&A Key Takeaways】**
- **Tariff Impact**: Low single-digit million impact on EOS imports, expected in H2 2025.
- **Robot Launch**: Navigation-integrated robotic system targeting Q4 2025 launch, with early feedback on screw placement accuracy.
- **International Growth**: Focused on Australia/New Zealand and Japan, with EOS adoption driving deformity procedure expansion.
- **Sales Force Efficiency**: Same-store sales growth 23% YoY, reflecting improved surgeon penetration and procedural share.
- **ASC Utilization**: Simple decompression cases leading, with PTP adoption in outpatient settings emerging.


Alphatec (ATEC)-1 May 25-2025 Q1 Earnings call transcript

- **Q4 2024 Super Growth**: 28% revenue surge ($177M) vs. 4x market rate, $9M cash flow, and 25% same-store surgical growth.
- **5-Year Momentum**: 40% CAGR, 19% surgeon adoption, 25% procedures – clinical differentiation driving share.
- **Japan Expansion**: First surgeries in Japan, targeting 15% lateral spine market share with EOS.
- **2025 Outlook**: $732M revenue (20% growth), $75M EBITDA, positive cash flow, and H2 robotics launch.
- **Disruption Play**: Stryker exit creating openings for ATEC's lateral leadership; EOS platform uniquely positioned.
- **Deformity Play**: EOS Insight adoption accelerating, with first deformity summit building academic partnerships.
- **Robotics Integration**: Navigation robotics H2 2025 to enhance screw placement accuracy while addressing systemic variables.


**【CEO Summary Section】**
- Q4 2024 revenue grew 28% YoY to $177 million, 4x the market growth rate, driven by surgical and EOS (3D imaging) segments.
- Achieved first-quarter cash flow of $9 million since transformation, with 25% same-store surgical revenue growth.
- 5-year CAGR of 40% in total revenue, 19% in surgeon adoption, and 25% in procedural volume, reflecting clinical differentiation.
- Expansion into Japan with first surgeries and a focus on lateral spine procedures, targeting the second-largest spine market globally.
- EOS Insight software adoption driving long-term implant pull-through and clinical insights for deformity surgeries.

**【CFO Financial Commentary】**
- Q4 2024 non-GAAP adjusted EBITDA of $21 million (12% margin), up 1,000+ basis points YoY, with $31 million full-year EBITDA.
- Surgical revenue grew $34 million YoY in Q4, largest absolute growth ever, fueled by 19% procedural volume and 7% ARPU growth.
- Gross margin held steady at 70%, with SG&A improving 850 basis points to 60% of sales due to infrastructure leverage and cost control.
- 2025 outlook: $732 million revenue (20% growth), $75 million EBITDA, and positive cash flow for full year, driven by operating leverage and EOS expansion.
- Free cash flow expected to turn positive in Q2+2025, with Q1 cash use of $15-20 million due to seasonality.

**【Q&A Key Highlights】**
- **Market Disruption & Sales Force**: CEO confident in current expense structure, with disciplined investment in salesforce expansion rather than aggressive spending.
- **Competitor Exit Opportunities**: Stryker's U.S. spinal exit creates openings for ATEC's lateral spine leadership, with EOS platform uniquely positioned to attract surgeons.
- **Japan Strategy**: Focused on lateral procedures with 15% market share target, leveraging EOS for pre-op planning and intra-op navigation.
- **PTP/LTP Penetration**: Early innings of PTP adoption, with $1 billion+ addressable market for lateral procedures vs. traditional posterior approaches.
- **Robotics Integration**: Navigation robotics launching H2 2025, complementing EOS for intra-op screw placement accuracy while addressing systemic variables like pre-op planning.
- **Deformity Growth**: First deformity summit with academic leaders, positioning ATEC as leader in EOS-driven deformity planning and PTP-based surgical solutions.
- **EOS Growth Trajectory**: 2025 EOS revenue guide of $75 million reflects cautious near-term outlook, but EOS Insight adoption poised to accelerate implant pull-through in 2026+.
- **International Expansion**: Australia/New Zealand driving 1-2% surgical revenue, with Japan and Europe as key 2025 growth markets.


Actual											-0.33	-0.25	-0.24	-0.35	-0.26	-0.39	-0.43	-0.4	-0.43	-0.1698	-0.1783	-0.1054	-0.1702	-0.1127	-0.1406	-0.1113	-0.181	-0.1429	-0.1082	-0.034	-0.1121	0.02	0.03	0.06
Forecast											-0.1925	-0.286	-0.2071	-0.26	-0.195	-0.1917	-0.2311	-0.3111	-0.2922	-0.2797	-0.2518	-0.204	-0.2088	-0.1763	-0.085	-0.0729	-0.155	-0.1163	-0.1069	-0.0543	-0.115	-0.0443	-0.0314	0.0378
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-71.43%	+12.59%	-15.89%	-34.62%	-33.33%	-103.44%	-86.07%	-28.58%	-47.16%	+39.29%	+29.19%	+48.33%	+18.49%	+36.07%	-65.41%	-52.67%	-16.77%	-22.87%	-1.22%	+37.38%	+2.52%	+145.15%	+195.54%	+58.73%

ATEC

ATEC fundamentals

ATEC Q4 2025 Earnings

Earnings Call

You can ask Aime

ATEC

ATEC fundamentals

ATEC Q4 2025 Earnings

Earnings Call

ATEC Earnings Call Summary for Q4/20254:30 PM on Feb 24, 2026

ATEC Earnings Call Summary for Q3/20254:30 PM on Oct 30, 2025

ATEC Earnings Call Summary for Q2/20254:30 PM on Jul 31, 2025

ATEC Earnings Call Summary for Q1/20254:30 PM on May 1, 2025

ATEC Earnings Call Summary for Q4/20244:30 PM on Feb 26, 2025

You can ask Aime